Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice Concerning Reduction of Capital Stock and Capital Reserves and Appropriation of Surplus
Notice of the Nomination of Candidates for the HEALIOS K.K. Board of Directors
FY2025 Financial Results (Material)
HEALIOS, Last Fiscal Year's Net Income Loss Narrows, Current period performance is undisclosed.
Start of ARDS Clinical Trial in Japan for the Global Phase 3 REVIVE-ARDS Study
HEALIOS, Last Fiscal Year's Undisclosed Net Income to Narrow
Announcement of Letter of Intent with Alfresa Corporation regarding the Sale and Purchase of Somatic Stem Cell Culture Supernatant
Healios Initiates Production of Culture Supernatant at In-house Cell Processing Facility
Submission of Clinical Trial Notification in Japan for the Global Phase 3 REVIVE-ARDS Study
(Delayed) Notice Regarding the Filing of a Lawsuit Against Healios
Announcement of Changes in Management and Organization
Development and Application Policy for HLCM051 (ARDS and Ischemic Stroke Treatment)
HEALIOS, Jan-Sep (Cumulative 3Q) Net Income Loss Narrows, Jul-Sep Net Income Turns to Profit
FY2025 Q3 Financial Results (Material)
Healios K.K. to Present at Jefferies Global Healthcare Conference
Announcement of Subgroup Analysis Results from the MUST-ARDS Trial Regarding Kidney Dysfunction
Healios K.K. to Present at Chardan's 9th Annual Genetic Medicines Conference
Notice Regarding the Termination of the Business and Capital Alliance Agreement with Nikon Corporation
Notice of Joint Research Agreement with Kyushu University on Immuno-Cell Therapy for Brain Tumors Using Healios’ Gene-Edited CAR-eNK Cells
Collaboration Between Minaris Advanced Therapies and Healios for the Commercial Manufacturing of Invimestrocel